Market News & Trends
Apricus Biosciences Announces NexACT Partner Has Completed pre-IND Meeting
Apricus Biosciences, Inc. recently announced its NexACT out-licensing partner, Exodos Life Science Limited Partnership, has completed a successful pre-IND meeting with the US FDA regarding…
Bend Research Signs Technology Licensing Agreement With Merck
Bend Research Inc., a leading independent drug formulation development and manufacturing company, recently announced it has entered into a licensing agreement with Merck, through a…
11/15/2011
Lundbeck & Otsuka Enter Long-Term CNS Agreement, Deal Has $1.8-Billion Potential Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S recently announced they have entered into…
Accentia Biopharmaceuticals to Sell Analytica for $10 Million
Accentia Biopharmaceuticals, Inc. recently announced it has entered into a series of agreements to strengthen its financial position, improve its balance sheet, and support ongoing…
Daiichi Sankyo to License ARQ 092 From ArQule
ArQule, Inc. and Daiichi Sankyo, Co. Ltd. recently announced the execution of a license agreement for the development of a new AKT inhibitor called ARQ…
Lundbeck & Otsuka Enter Long-Term CNS Agreement, Deal Has $1.8-Billion Potential
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S recently announced they have entered into a long-term agreement for the development and commercialization of up to…
NeuroDerm Announces Positive Phase II Results of Dermal Patch for Patients with Parkinson's
NeuroDerm, Ltd. recently announced the results of a Phase I/II safety and pharmacokinetic trial of ND0611, administered as an adjunct therapy to Sinemet, Sinemet CR,…
Positive Phase II Results Reported for Sanofi/Regeneron Pharmaceuticals Cholesterol Drug
Sanofi and Regeneron Pharmaceuticals, Inc. recently announced positive preliminary results from the Phase II study program in which patients with elevated low-density lipoprotein cholesterol (LDL-C)…
Salix Pharmaceuticals to Acquire Oceana Therapeutics for $300 Million
Oceana Therapeutics LLC, a privately owned global company focused on commercializing best-in-class specialty therapeutics, recently announced it has entered into a definitive agreement for the…
GSK to Use Alnylam Pharmaceuticals' RNAi Technology for Vaccine Production
Alnylam Pharmaceuticals, Inc. recently announced it has formed a collaboration with GSK focused on Alnylam's VaxiRNA technology for certain GSK vaccine products, including influenza. VaxiRNA…
Repligen Buys Novozymes Biopharma Unit
Repligen Corporation recently announced the execution of a definitive agreement to acquire the business of Novozymes Biopharma Sweden AB in a cash transaction of $22.7…
11/8/2011
Gateway Analytical Growth Demands Move to a Larger Facility Gateway Analytical recently announced the company will move to a larger facility at 5316 William Penn…
CoreRx Adds Precision Powder Microdosing System to its Development Capabilities
CoreRx recently announced it has further enhanced its offering by adding an Xcelodose precision powder microdosing system to its Product Development capabilities in response to…
Evonik Acquires Pharmaceuticals Business of SurModics
Evonik Industries AG recently announced it has reached an agreement to acquire the Pharmaceuticals business of SurModics, Inc. headquartered in Eden Prairie, MN. The signing…
Gateway Analytical Growth Demands Move to a Larger Facility
Gateway Analytical recently announced the company will move to a larger facility at 5316 William Penn Highway, Gibsonia, PA, after outgrowing the current laboratory and…
Gilead Submits NDA to FDA for Quad Tablet
Gilead Sciences, Inc. recently announced it has submitted an NDA to the US FDA for marketing approval of the Quad, a complete single-tablet regimen of…
11/01/2011
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that…
3M DDS Announces New VP & General Manager
3M Drug Delivery Systems recently announced the appointment of James Ingebrand as the new Vice President and General Manager after the retirement of his predecessor,…
Activartis Develops Cancer Vaccine in Phase II, Seeks Partner
Activartis GmbH (formerly Trimed Biotech GmbH) recently announced it is developing a cancer immunotherapy concept that is currently in Phase II clinical trials. Initially directed…
Acton Pharmaceuticals Announces License Agreement for Nasal Aerosol
Acton Pharmaceuticals, Inc. recently announced it has completed a licensing agreement with Sanofi US for prescription NASACORT HFA (triamcinolone acetonide) Nasal Aerosol for the treatment…
